AASLD
THE LIVER MEETING
2016
NOVEMBER 11-15
BOSTON
URVAL FRÅN PROGRAMMET
Välkomna till det 67:e amerikanska levermötet
“The Liver Meeting” arrangerat av The American
Association For the Study of Liver Diseases (AASLD)
I år är mötet åter igen på John B. Hynes Veterans Memorial Convention Center i Boston och vi
kan förvänta oss några intensiva dagar av ny HCV data och innovationer, tex nästa generations
HCV-behandlingar.
Detta dokument innehåller ett urval av intressanta presentationer och posters inom HCV eller
med svenska författare (svensk flagga) som kommer att presenteras på kongressen.
AbbVies presentationer har markerats med AbbVielogga. Om du läser detta dokument som PDF
i elektronisk form är programpunkterna under ”Program-at-a-Glance” nedan klickbara och leder
till respektive punkt på mötets hemsida för mer information.
Det fullständiga konferensprogrammet finns tillgängligt här:
http://www.aasld.org/events-professional-development/liver-meeting/program-0
Abstracts till all data som presenteras går att ladda ner på följande länkar:
Plenary, parallel and poster sessions:
http://aasldpubs.onlinelibrary.wiley.com/hub/issue/10.1002/hep.v64.S1
Late-breaking abstracts:
http://www.aasld.org/sites/default/files/LBA%20Full%20Abstracts%20Final%20%28
Trimmed%29_1.pdf
Slutligen kan vi tipsa om poster #738: ”Higher risk of renal disease in chronic hepatitis C
patients, and treatment improved survival for hepatitis C patients on hemodialysis – a nationwide population-based register study from 2001 to 2014” som presenteras som en Poster of
Distinction under Poster Session II (HCV: Epidemiology and Natural History)
kl. 17:30-19:00, lördag 12 november, av Jonas Söderholm från AbbVie Sverige.
Väl mött i Boston
Jan Kövamees
Medicinska avdelningen
AbbVie Sverige
Highlightmöte
med gemensam middag
fredagen den 11/11
(anmälan till Jonas Johansson
+46 70 5628184)
Program-at-a-Glance
Friday 11 November
08:00 -15:15
Room 304/306
08:00 -17:30
Hall C
15:30 -18:00
Ballroom A
15:30 -19:20
Ballroom C
Program-at-a-Glance
Saturday 12 November
08:00 - 16:40
Ballroom B
Basic Science Symposium
Liver Immunology
08:00 - 17:00
Auditorium
and Balcony
Postgraduate Course
Challenges in the Management of Common Liver Diseases
11:40 - 13:05
TBD
Meet-the-Professor Luncheons
14:00 - 19:30
Hall C
Poster Session II
Presentation time 17:30 - 19:00
Posters of interest are listed separately below under “Poster presentations”
– HCV: Epidemiology and Natural History (737-845)
– Hepatitis C: New and Approved Agents I (846-966)
17:00 - 19:30
Exhibits Open
17:00 - 19:30
Opening Reception
19:30 - 22:00
Industry-supported Satellite Symposia
Program-at-a-Glance
Sunday 13 November
06:45 - 07:45 TBD
Early Morning Workshops
08:00 - 09:30
Parallel Session A
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 1: HCV Virology
08:00 - 17:30 Hall C
Poster Session III and Late-breaking Poster Session
Presentation time 12:30 - 2:00
Posters of interest are listed separately below under “Poster presentations”
– Late-breaking Posters (LB13-LB36)
– Clinical Hepatocellular Carcinoma (1236-1368)
– HCV Therapeutics: Preclinical and Early Development (1448-1456)
– HCV: Virology and Pathogenesis (1457-1498)
09:30 - 10:00
Auditorium and Balcony
Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture
Zen and the Art of Liver Transplantation Quality
09:30 - 15:00
Exhibits Open
10:00 - 11:30
Ballroom A
Parallel Session B
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 3: Hepatitis C: Treatment Outcomes
14:00 - 14:30
Auditorium
and Balcony
Story
14:30 - 14:45
Auditorium and Balcony
Award Presentation
Distinguished Clinician Educator/Mentor
15:00 - 16:30
Auditorium
and Balcony
President’s Choice Lecture
How Drinking Like a Fish Leads to Sleeping With the Fish: An “Old-Fashion”
General Hepatology Update
15:00 - 16:30
Back Bay ABC
Room 309
Ballroom BC
16:45 - 18:15
Room 312
Auditorium and Balcony
Room 309
18:30 - 21:00
Parallel Session E
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 8: HCV: Epidemiology and Natural History of HCV I
– Parallel 9: HCV: Resistance and Immune Response
– Parallel 11: Hepatitis C: New and Existing Agents
Parallel Session F
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 14: Allocation and Innovative Therapies
– Parallel 17: Hepatitis C: Phase 2/3 Trials
– Parallel 18: Mechanisms and Consequences of Drug-induced Liver Injury
Industry-supported Satellite Symposia
Program-at-a-Glance
Monday 14 November
06:45 - 07:45
Early Morning Workshops
08:00 - 09:30 Auditorium
and Balcony
Presidential Plenary (Clinical)
08:00 - 17:30
Hall C
Poster Session IV
Presentation time 12:30 - 2:00
Posters of interest are listed separately below under “Poster presentations”
– Hepatitis C: New and Approved Agents II (1911-2030)
– Infections and Acute on Chronic Liver Failure (2031-2063)
09:30 - 10:00
Auditorium and Balcony
Award Presentations
Distinguished Service and Achievement Awards
09:30 - 15:00
Exhibits Open
10:00 - 11:30
Parallel Session H
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 26: Clinical Hepatocellular Carcinoma and Cholangiocarcinoma
– Parallel 27: HCV: Epidemiology and Natural History II
Room 311
Back Bay ABC
10:00 - 10:30 Auditorium
and Balcony
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture
Idiosyncratic DILI – Lessons Learned from Bedside to Bench
10:30 - 12:00
Room 302/304
Emerging Trends Symposium (The Challenge of Providing Value-Based Care
for the Patient With Cirrhosis)
11:00 - 12:00
TBD
AASLD Panel Discussion on Medicaid and Access to HCV Medications
11:00 - 12:30
Ballroom BC
Presidential Plenary (Basic)
14:15 - 14:45
Hans Popper State-of-the-Art Lecture
Hepatic Fibrosis: A Translational Success Story
Auditorium and Balcony
14:45 - 15:00
Auditorium
and Balcony
Presidential Address
15:00 - 16:30
Auditorium
and Balcony
Late-breaking Oral Session I
15:00 - 16:30
Parallel Session I
Presentations of interest are listed separately below under “Oral presentations”
– Parallel 29: Hepatitis C: Retreatment and Resistance
– Parallel 32: Viral Hepatitis and Interventions in Liver Transplantation
Ballroom BC
Room 210
16:00 - 18:00
Auditorium
and Balcony
Special Interest Group Program
Hepatitis C: Treatment Challenges in the DAA Era (Hepatitis C SIG)
18:30 - 21:00
Industry-Supported Satellite Symposia (AbbVie: Addressing Practical
Challenges in HCV Management), Sheraton Boston Hotel – Grand
Ballroom
Program-at-a-Glance
Tuesday 15 November
06:45 - 07:45
Early Morning Workshops
08:00 - 09:30
Auditorium
and Balcony
Late-breaking Oral Session II
09:30 – 11:00
Auditorium
and Balcony
Presidential Plenary (Viral Hepatitis)
11:30 - 12:00
Auditorium and Balcony
Hepatitis Debrief
This session provides a synthesis of new data on the treatment of viral
12:00 - 12:30
Auditorium and Balcony
Leon Schiff State-of-the-Art Lecture
Elimination of Hepatitis B: Is it possible?
12:30 - 13:00
Auditorium Balcony Clinical Hepatology Debrief
This newly added session is designed to complement the highly-regarded, and
hepatitis presented at The Liver Meeting.
Hepatitis Debrief, and will review key clinical highlights from the meeting.
Oral presentations
Sunday 13 November
08:00-09:30
Room 210
Parallel A/1: HCV Virology
7: Hepatitis C virus-induced epigenetic reprogramming as driver of hepatocarcinogenesis and target for cancer chemoprevention
10:00-11:30
Ballroom A
Parallel B/3: Hepatitis C: Treatment Outcomes
19: Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs
20: Uptake of and factors associated with direct-acting antiviral therapy among
patients infected with hepatitis C virus in the Chronic Hepatitis Cohort Study,
2014-2015
21: Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir and Paritaprevir/
Ritonavir/Ombitasvir and Dasabuvir-Based Antiviral Regimens for Hepatitis C
in 17,847 patients in the Veterans Affairs National Healthcare System
22: High Efficacy in Real-World Treatment of Cirrhotic Patients by NonSpecialist Providers
23: Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with
Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics
24: Cost Effectiveness Analysis of Pre vs. Post LT Treatment with All Oral
Direct Acting Antivirals in Hepatitis C Patients with Hepatocellular Carcinoma
in the US
15:00-16:30
Back Bay ABC
Parallel E/8: HCV: Epidemiology and Natural History of HCV I
55: Decreasing Mortality in Hepatitis C Patients Awaiting Liver Transplantation
in the Direct Acting Antiviral Era
56: Factors associated with mortality, independently of sustained virological
response (SVR), in HIV/HCV co-infected subjects - ANRS CO13 HEPAVIH
cohort
57: Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a U.S.
Cohort of 2376 Patients with Chronic Hepatitis C (CHC) and Cirrhosis
58: Impact of all-oral antiviral therapy on portal pressure and hemodynamics on
HCV-infected cirrhotic patients
60: Impact of drug use and opioid substitution therapy on hepatitis C reinfection: The BC Hepatitis Testers Cohort
15:00-16:30
Room 309
Parallel E/9: HCV: Resistance and Immune Response
61: Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants (RAVs) After Treatment With Grazoprevir-Containing Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection
62: Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+
tissue-like memory B-cell
63: Multiple HCV Amino Acid Variants Associate with Interferon Lambda Polymorphism in Genotype 1a, 1b and 3a Infections
64: Hepatitis C virus reactivation in patients with cancer: A prospective
observational study of 91 patients
65: Virus-induced IFN-α 4 potently blocks IFN--α signaling by ISG15/USP18
in HCV infection: implication for increased IFN responsiveness after DAA
treatment
15:00-16:30
Ballroom BC
Parallel E/11: Hepatitis C: New and Existing Agents
73: ENDURANCE-2: Safety and Efficacy of ABT-493/ABT-530 in Hepatitis C
Virus Genotype 2-infected Patients without Cirrhosis, a Randomized,
Double-Blind, Placebo-Controlled Study
74: C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naïve and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks
75: Integrated Analysis of SOF+RBV, LDV/SOF or SOF/VEL for the Treatment
of Genotype 4 Chronic HCV Infection
76: Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve Subjects
with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III
Randomized Multinational Clinical Trial
77: Single-Centre, Dose Escalation, Open-Label Phase 1 Trial of the
experimental anti-fibrotic small molecule PRI-724 in Patients with Hepatitis C
virus related Cirrhosis
78: Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected
Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings
16:45-18:15
Auditorium
and Balcony
Parallel F/17: Hepatitis C: Phase 2/3 Trials
109: A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/
Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct Acting Antiviral
Experienced Patients with Genotype 1-6 HCV Infection: The POLARIS-4 Study
110: Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/
Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic
Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)
111: RG-101 in Combination with 4 Weeks of Oral Direct Acting Antiviral
Therapy Achieves High SVR Rates in Treatment Naïve Genotype 1 and 4
Chronic Hepatitis C Patients
112: High Sustained Virologic Response (SVR) Rates in Patients with Chronic
HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/
MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of
C-CREST-1 & 2)
113: SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients
with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience
and/or Cirrhosis
114: ENDURANCE-4: Efficacy and Safety of ABT-493/ ABT-530 Treatment in
Patients with Chronic HCV Genotype 4, 5, or 6 Infection
Oral presentations
Monday 14 November
10:00-11:30
Room 311
Parallel H/26: Clinical Hepatocellular Carcinoma and Cholangiocarcinoma
169: Effectiveness of direct antiviral agents for hepatitis C virus in 624 patients
with hepatocellular carcinoma in the Veterans Affairs Healthcare System
173: Genome-Wide Association Study (GWAS) for Chronic Hepatitis C-Related Hepatocellular Carcinoma (HCC)
10:00-11:30
Back Bay ABC
Parallel H/27: HCV: Epidemiology and Natural History II
175: The impact of sustained virological response to HCV infection on long
term risk of hepatocellular carcinoma: The BC Hepatitis Testers Cohort
176: Liver-related morbidity and mortality in patients with Chronic Hepatitis C
and cirrhosis with and without sustained virologic response
177: 4AGP – A novel algorithm using indirect biomarkers out-performs established scores for detecting patients with elevated liver stiffness
178: Transmission Rates And Outcomes in Hepatitis C Virus Positive Donor to
Hepatitis C Virus Negative Kidney Transplant Recipients: Analysis of National
Data
179: Comprehensive Care Coordination Reduces Disparities in Access to
Hepatitis C Care and Treatment in Highly Complex Patients
180: Hepatitis C Complications: Prevalence and Disparities in a Large US
Cohort 2006-2014
11:00-12:30
Ballroom BC
Presidential Plenary (Basic)
185: Decreased Intestinal Glucose Absorption in Healthy Volunteers Treated
with the FXR Agonist Obeticholic Acid
15:00-16:30
Ballroom BC
Parallel I/29: Hepatitis C: Retreatment and Resistance
193: Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/
Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic
HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen
(C-SURGE)
194: Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in
NS5A Inhibitor-Experienced Patients with Genotype 1-6 Infection: The Phase 3
POLARIS-1 Study
195: Distinct Evolutionary Pathways of NS5A Inhibitor Resistance in Patients
With Genotype 1a Versus 1b Infection During Monotherapy With MK-8742
(Elbasvir)
196: Quasispecies of HCV is not necessary for emerging resistance-associated
substitution of HCV after DAA treatment
197: Complex Pattern of Resistance-Associated Substitutions of Hepatitis C
Virus after Treatment failure of Interferon-Free Daclatasvir plus Asunaprevir
regimen
198: Impact of resistance-associated substitutions (RASs) on the selection and
the efficacy of interferon-free DAA therapies in genotype 1: interim analysis
from large scale nation-wide study by Japanese Red Cross Liver Study Group
15:00-16:30
Room 210
Parallel I/32: Viral Hepatitis and Interventions in Liver Transplantation
212: Successful pre- and post liver transplant Sofosbuvir based anti HCV treatment in persons living with HIV infection
213: Efficacy and safety treating the recurrent hepatitis C post-liver transplantation with Simeprevir and sofosbuvir: The Spanish experience (SETH)
16:45-18:15
Ballroom BC
Parallel J/34: Health Care Delivery and Access to Care
227: Towards eradication of hepatitis C virus infection in the Veterans Affairs
national healthcare system: a study of 107,079 antiviral treatment regimens
administered from 1999-2015
Oral presentations
Tuesday 15 November
08:00-09:30
Auditorium
and Balcony
Late-breaking Oral Session II
LB-10: Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular
Carcinoma (HCC): the CheckMate 040 Study
LB-11: EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with renal
impairment and Chronic Hepatitis C Virus Genotype 1-6 Infection
LB-12: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for
8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve
Genotype 1-6HCV-Infected Patients: The POLARIS-2 Study
09:30-11:00
Presidential Plenary (Viral Hepatitis)
Auditorium and
Balcony
253: ENDURANCE-1: Efficacy and Safety of 8- versus 12-week Treatment
with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection
254: Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List
255: Characterization of HEV kinetics during ribavirin monotherapy post
transplantation
256: Paired Liver biopsy, Fibrotest and FibroScan® before and after treatment
with DAA in liver transplanted recipients with recurrent hepatitis C: diagnostic
accuracy and concordance
257: Trends in Indications for Liver Retransplantation: Recurrent HCV progressively declining
258: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8
Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3
HCV Infection and Cirrhosis: The POLARIS-3 Study
Poster presentations
Friday 11 November
08:00 - 17:30: Poster Session I, Hall C
Presentation time: 12:00 - 13:30
Bilirubin and Bile Acid Transport (296-309)
307
The autophagy inhibitor Rubicon is a direct target of the bile acid receptor FXR in human liver and is induced in human cholestasis
Hemochromatosis, Wilson Disease (559-574)
572
EXPLORE: A prospective, multinational natural history study of acute hepatic porphyria patients with recurrent attacks
Hepatitis B: Immunology and Virology (575-633)
587
Characterization of T cell responses after stopping HBV therapy with nucleos(t)ide analogues (NA) in HBeAg-negative patients
Liver Transplant in Children (666-667)
666
Graft fibrosis after paediatric liver transplantation: 20 years of follow-up
Pediatric Viral and Autoimmune Hepatitis (705-715)
706
Sofosbuvir + Ribavirin for 12 or 24 Weeks Is Safe and Effective in Adolescents with
Genotype 2 or Genotype 3 Chronic Hepatitis C Infection
Poster presentations
Saturday 12 November
14:00 - 19:30: Poster Session II, Hall C
Presentation time: 17:30 - 19:00
HCV: Epidemiology and Natural History (737-845)
738
Higher risk of renal disease in chronic hepatitis C patients, and treatment improved survival for hepatitis C patients on hemodialysis – a nationwide population-based register study
from 2001 to 2014
739
Risk of incident liver cancer following HCV treatment with sofosbuvir-containing
regimens
742
Comparing Child-Pugh, MELD and FIB-4 Scores to Predict Mortality, Hepatic Decompensation and Hepatocellular Carcinoma in HCV Infected Persons: ERCHIVES Study
744
Natural NS3, NS5A and NS5B HCV resistance is common in real practice, differently
associated to HCV genotypes and response to NS5A inhibitors
745
In The Era of Highly Effective Direct Acting Anti-Viral Agents, Screening The Entire United
States Population for Hepatitis C is Cost Effective
748
Improved Hepascore values in HCV accurately predicts reversal of risk of hepatocellular
carcinoma, liver decompensation and liver related death
749
Identification of Patient Groups Previously Not Candidates for Interferon Therapy for
Chronic Hepatitis C and Implications for Planning and Budgeting for Treatment with
Current Regimens
753
Polaris Observatory - Global prevalence of hepatitis C
755
Assessing Risk of Hepatic Decompensation, Hepatocellular Carcinoma, and Transplant
Free Survival for Patients with both Early Stage and Advanced Chronic Hepatitis C
760
Impact of treatment induced vs spontaneous HCV clearance on the long term risk of
hepatocellular carcinoma: BC Hepatitis Testers Cohort
761
Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C
Infection in France
770
Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection
776
The prediction of hepatocellular carcinoma development and overall survival in chronic
hepatitis C using liver stiffness measurement: a long-term outcome study
785
Chronic Hepatitis C Virus Infection Increases Risk of Cardiovascular Disease and Chronic
Kidney Disease in the United States
798
Cross-sectional Study of Chronic Kidney Disease Prevalence in association with Monoinfected patients Hepatitis C virus in ANRS CO-22 Hepather cohort
799
Prevalence of naturally occurring HCV NS5A resistance-associated substitutions by
high-resolution sequencing technology in treatment naive genotype 1 patients
804
Direct-acting antiviral treatment patterns among hepatitis C patients with advanced
chronic kidney disease: a retrospective cohort study
809
Viral eradication reduces all-cause mortality in chronic hepatitis C patients with advanced
liver fibrosis: a propensity score analysis
811
Predicting Hepatocellular Carcinoma in Hepatitis C Patients by Analysis of APRI Score
Progression Pattern
813
Comparing APRI and FibroScan score for pre-treatment assessment of HCV-related liver
disease in community settings
815
Non-invasive assessment of liver fibrosis and cirrhosis regression in chronic hepatitis C
patients treated with pan-oral direct-acting antivirals
820
Chronic Hepatitis C Virus Infection and Cancer Risks: A Population-based Cohort Study
822
Regression of Liver Fibrosis Stage in Chronic Hepatitis C Infected Patients After Achieving
Sustained Virologic Response Using Direct-Acting Antivirals as Demonstrated by Elastography
823
Leveraging the EHR to Eliminate HCV: Automated Birth Cohort Prompting Within a Large
Healthcare System
824
Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic
Hepatitis C who Achieved Sustained Virologic Response after DAAs Treatment
828
Hepatitis C Virus infection and Risk of Venous Thromboembolism: A Systematic Review
and Meta-analysis
829
To determine the order of influence that patient demographics and clinical conditions
have on access to new Direct Acting Antiviral Agents (DAAs) in the EU5
835
Effect of Direct Acting Antiviral Hepatitis C Drugs on Fibrosis Stage Over Time Using
APRI and FIB-4 Scores
839
Patients who Fail Treatment in the era of DAAs: Projections from HEP-SIM Model
842
Higher Prevalence of Existing Comorbidities and Medication Use in Untreated Patients
with Chronic Hepatitis C (CHC) compared to Treated Patients: A Population-Based
Study in Post- Oral Direct-Acting Antivirals (DAAs) Era
843
Foundation for a Clinical Intervention on Hepatitis C: A 2015 Survey of New York City
Hospitals’ Capacity to Cure
845
Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with
recent Hepatitis C virus infection, including for post-treatment relapse
Hepatitis C: New and Approved Agents I (846-966)
846
Integrated Resistance Analyses of HCV-infected Patients treated with Sofosbuvir,
Velpatasvir and Voxilaprevir for 8 and 12 weeks from Phase 2 Studies
847
Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1
monoinfection: Final results of the The German HepNet Acute HCV IV Study
848
Cost Effectiveness Analysis of Pre vs. Post LT Treatment with All Oral Direct Acting
Antivirals in Hepatitis C Patients with Decompensated Cirrhosis in the US
849
Analysis of HCV Variants in the MAGELLAN-1 Part 1 Study: ABT-493 and ABT-530
Combination Therapy of Genotype 1-Infected Patients Who Had Failed Prior Direct
Acting Antiviral-Containing Regimens
850
A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir/
Velpatasvir for Patients with Chronic Hepatitis C Virus Genotypes 1 to 6 and Decompensated Cirrhosis in the US
851
Final Results from Phase 3 Portion in Phase 2/3 Study of Elbasvir / Grazoprevir in Hepatitis
C Genotype 1 Infected Japanese Patients
852
Pharmacokinetics of Sofosbuvir/Velpatasvir and Tenofovir in Subjects with HCV/HIV
Coinfection Using Boosted or Unboosted Antiretroviral Regimens
853
Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of
Elbasvir / Grazoprevir in Hepatitis C Genotype 1 Infected Japanese Patients
854
Drug-drug interactions between direct acting antivirals ABT-493 and ABT-530 with
angiotensin II receptor blockers (losartan or valsartan)
855
Hemodialysis does not affect the pharmacokinetics of ABT-493 or ABT-530
856
A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir/
Velpatasvir for Patients with Chronic Hepatitis C Virus Genotype 1 Infection in the US
857
Gender Differences in Patients Treated for HCV: Efficacy and Safety of Sofosbuvir/
Velpatasvir in Women
858
A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotype 2 and 3 Infection in the US
860
Hepatocellular carcinoma development in hepatitis C virus patients who achieved
sustained viral response by interferon therapy and direct anti-viral agents therapy
861
Clinical And Immunological Effect Of Direct Acting Antivirals In Patients With Hepatitis C
Virus-Associated Cryoglobulinemic Vasculitis
862
Sofosbuvir and Ribavirin is safe and effective therapy in chronic hepatitis C patients with
end-stage renal disease on haemodialysis
864
The Safety and Tolerability of Sofosbuvir/Velpatasvir with Weight Based Ribavirin in
Patients with Child-Pugh Class B Cirrhosis in the ASTRAL-4 study
865
Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving
Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir ± Ribavirin: First interim Safety and
Efficacy Results from TOPAZ-I
866
Combined resistance, demographic, and phylogenetic analyses of HCV genotype
4-infected patients treated with ombitasvir/paritaprevir/r ± ribavirin in the PEARL-I and
AGATE-1 studies
867
Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in
Patients with Mild or Moderate Renal Impairment
868
Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical
Practice: HCV-TARGET International Consortium
869
Concomitant Proton Pump Inhibitor Use Does Not Reduce the Efficacy of Elbasvir/
Grazoprevir
870
Protease inhibitor resistance remains even after mutant strains become undetectable
using ultra-deep sequencing
871
HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in
patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study
872
GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with
Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection
without Cirrhosis
873
ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian
Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized,
Double-Blind, Placebo-Controlled Study
874
High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT)1b
Infection Treatment With Elbasvir/ Grazoprevir for 12 Weeks: An Integrated Analysis
875
ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C
Virus Infection and Compensated Cirrhosis
876
Long-term follow-up of patients with chronic HCV infection treated with daclatasvir-based regimens in phase 2 and 3 studies
877
Treating non-cirrhotic Hepatitis C patients in the UK is a cost-saving intervention
878
Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected
Pediatrics Aged 6 to <12Years Old
879
Ledipasvir/Sofosbuvir in Egyptian Patients with Chronic Genotype 4 HCV Infection
880
Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or
Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens
881
Variables associated with treatment outcomes for hepatitis C genotype 1 infection with
direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)
882
Treatment of HCV in the Department of Corrections (DOC) in the era of Oral Direct
Acting Antivirals (DAA)
883
8 weeks treatment under real life conditions with Ledipasvir/Sofosbuvir in HIV coinfected treatment-naïve HCV genotype 1 patients demonstrates similar results to
mono-infected HCV patients: data from the German Hepatitis C-Registry (DHC-R)
885
QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3
Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or
Without Ribavirin
886
RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir with or
without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
with Severe Renal Impairment or End-Stage Renal Disease
887
Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/
ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients – predictors
and clinical significance
888
Reduced ITPase Activity Protects Against Ribavirin-Induced Anemia, but does not
Predict Virologic Response in Interferon-free, Ribavirin Containing Regimens
889
Elbasvir/Grazoprevir (EBR/GZR) Does Not Worsen Renal Function in Patients With
Hepatitis C Virus (HCV) Infection and Pre-existing Renal Disease
892
Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected
With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World
Cohorts
893
New resistance-associated variants and failure of dual oral therapy with daclatasvir and
asunaprevir
894
Retreatment of Patients Who Failed Direct-acting Antiviral (DAA) Therapies: Real World
Experience from a Large European Hepatitis C Resistance Database
895
Outcomes of Sofosbuvir and Daclatasvir rescue therapy in decompensated Hepatitis C
cirrhotics with MELD ≥ 15: final results of the Australian TOSCAR study
896
Does successful viral eradication translate into beneficial long-term clinical outcome of
patients with advanced liver disease due to hepatitis C after DAA therapy?
897
Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir Plus Ribavirin in Daily Practice Hepatitis C
Virus Genotype 1- or 4-Infected Patients with Compensated Cirrhosis
898
Retreatment Of HCV DAA Failures In Real Life: HCV Infection May Be Always Curable
899
Factors Associated with Persistent Alanine Aminotransferase Elevation in Patients
Treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir
900
Daclatasvir Plus Sofosbuvir Plus RIbavirin in HCV Genotype 3 Infected Patients with
Cirrhosis Child A: A Randomized Trial for 16 or 24 Weeks (NCT #02304159)
902
Does Paritaprevir/ritonavir, Ombitasvir, Dasabuvir Combination Increase the Risk of
Hepatic Decompensation and Renal Insufficiency in Patients with Cirrhosis?
903
Real World Efficacy of Antiviral Treatment in Chronic Hepatitis C Genotype 3 Infection:
Data from the German Hepatitis C-Registry (DHC-R)
904
Safety and efficacy of IFN- free antiviral therapies in advanced HCV- associated liver
cirrhosis: Results from the German Hepatitis C-Registry (DHC-R)
905
Safety And Efficacy Of The Combination Ombitasvir/ Paritaprevir/Ritonavir ± Dasabuvir
In Hcv Genotype 1- Or 4-Mono-Infected Patients From The French Anrs CO22 Hepather
Cohort
908
Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients
and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not
Achieve SVR after 16 or 24 Weeks of Sofosbuvir + Ribavirin
909
Predictors of Improvement in Glomerular Filtration Rate Among Patients Treated with
Ombitasvir/Paritaprevir/r and Dasabuvir with or without RBV
911
Alcohol use and hepatitis C virus treatment outcomes among 15,151 patients receiving
direct antiviral agents
914
Efficacy and Safety of DAAs therapy in Hepatitis C: A Multicenter Real-world Cohort of
Chronic Hepatitis C Patients
916
A program of Testing and Treat Intended to Eliminate Hepatitis C in a Prison: The J
AILFREE-C study
921
Four weeks of sofosbuvir, ledipasvir and ribavirin with or without interferon give high cure
rates in drug users with hepatitis C - a randomized controlled trial (4WIDUC)
922
Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV/SOF FDC) for 8 Weeks for Treatment-Naïve, Noncirrhotic Hepatitis C Genotype 6 (HCV-6) and for 12 Weeks for Those
With Cirrhosis and/or Prior Treatment Failure: An Open-Labeled Clinical Trial
924
Sofosbuvir/Ledipasvir plus Ribavirin achieves high SVR12 in genotype-3 patients with
compensated cirrhosis and similar to Sofosbuvir plus Daclatasvir. A multicentre real life
cohort
925
Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat
hepatitis C recurrence after liver transplantation only in genotype 1. Results from the
CO23 ANRS CUPILT study
929
Community-Based Real World Outcomes of Sofosbuvir/Ledipasvir Without Ribavirin in
the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States
930
Real-world SVR Rates for Paretaprevir/ritonavir, Ombitasvir, Dasabuvir vs. Sofosbuvir/
ledipasvir Regimens With and Without Ribavirin
931
Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with
Concomitant Acid Suppressing Medication
932
Effectiveness of DACLATASVIR plus SOFOSBUVIR in HCV-GT3 patients – Results from
the German Hepatitis C Registry (DHC-R)
933
Improvement of renal function associated to sustained viral response in patients with
chronic infection by hepatitis C virus (HCV) and renal insufficiency
934
Exposure-Response Analyses to Demonstrate Similar Efficacy and Better Tolerability
for Low Dose Ribavirin Compared to Weight based Ribavirin with the 3D Regimen
(Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) in HCV GT1 Infection
935
RUBY-II: Efficacy and Safety of a Ribavirin-free Ombitasvir/ Paritaprevir/Ritonavir ±
Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease
and HCV Genotypes 1a or 4 Infection
937
In patients with chronic HCV infection, antiviral treatment with DAAs can be managed by
specialized nurses. Results of a large real-life cohort
938
Hepatitis C Treatment with Direct Acting Antiviral Therapy: Report of a Global Survey
942
Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from
RESIST-HCV, a large regional database
944
Successful hepatitis C treatment in advanced cirrhosis with DAA reduces HCC incidence
946
Investigation of the prevalence and characteristics of RAVs in DAA-naive and –
experienced European patients
947
The Impact of Concomitant Acid Reducing Therapy (ART) on Sustained Virologic
Response (SVR-12) Among Genotype 1 Infected Chronic Hepatitis C (CHC) Patients
Treated with Ledipasvir/Sofosbuvir (LDV/SOF) With or Without Ribavirin
948
Real-World Retreatment of Sofosbuvir/Ledipasvir (SOF/LDV) Failures In Hepatitis C
Virus Genotype 1 infection
950
Safety and efficacy of daclatasvir plus asunaprevir combination therapy in hemodialysis
patients infected with hepatitis C virus genotype 1b
951
Real-World Effectiveness and Safety of DAA Combination Therapies in Elderly Patients
> 70 Years of Age in the German Hepatitis C-Registry (DHC-R)
952
Frequency and predictive value of detectable HCV RNA at the end of treatment with
ledipasvir/sofosbuvir ±ribavirin in a large real world cohort: Results from the German
Hepatitis C-Registry (DHC-R)
954
Improved Hepatic Profile in Hepatitis C Virus (HCV) Genotype (GT) 4-Infected Egyptian
Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with
Ribavirin (AGATE-II)
956
High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients
Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials
957
Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients
predominantly with cirrhosis – the Australian REV1TAL Study
958
Regression of fibrosis in HCV patients treated with direct acting antivirals (DAAs)
959
Comparison of Health-Related Quality of Life (HRQL) in Asian Patients with Chronic
Hepatitis C Treated with Interferon (IFN)-free Ribavirin (RBV)-Containing Regimens
vs Interferon-free and Ribavirin-free Regimens
961
Effectiveness And Safety Of Ombitasvir, Paritaprevir/Ritonavir And Sofosfuvir/
Ledipasvir In Patients With Genotype 4 Chronic Hepatitis C Virus Infection: Results
From The Spanish Real World Cohort
962
Preliminary clinical outcome data among patients with hepatitis C virus infection receiving direct-acting antiviral therapy in the Chronic Hepatitis Cohort Study, 2014-2015
963
An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection:
Efficacy and Safety Results of TOPAZ-VA
964
Viral response to hepatitis C direct-acting antivirals significantly improves diabetes
control
965
The potential impact of drug-drug interactions (DDIs) in the selection of direct acting
antivirals (DDAs) in the current treatment of chronic hepatitis C (CHC) in routine
clinical practice
966
Ledipasvir/Sofosbuvir + Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated
HCV Genotype 1 Patients: SOLAR-1 and -2 Studies Compared to a Real-World Dataset
Immunosuppression and Liver Transplant (967-1017)
973
Everolimus with low-dose calcineurin inhibitor in pediatric liver transplant recipients:
12-month results of the H2305 study
Steatohepatitis: Clinical and Therapeutic (1050-1186)
1050 Long Term Mortality of Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
1053 Fibrosis progression and mortality in non-alcoholic fatty liver disease
1054 Risk factors for type 2 diabetes mellitus development in non-alcoholic fatty liver disease
after up to 41 years follow-up
1095 Risk of Mortality by Fibrosis Stage in NAFLD: A Systematic Review and Meta-Analysis
1098 Effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and free omega-3
carboxylic acids on liver steatosis and hepatocyte damage biomarkers in Type 2 diabetes
patients with non-alcoholic fatty liver disease
Poster presentations
Sunday 13 November
08:00 - 17:30: Poster Session III and Late-breaking Poster Session, Hall C
Presentation time: 12:30 - 14:00
Late-breaking Posters (LB13-LB36)
LB-14
A Novel Single Daily Fixed Dose Combination of Sofosbuvir 400 mg + Ribavirin
1000 mg + EGCG400 mg is Superior to the Standard of Care as an Anti-Viral and Safer
Causing less Hemolysis in Patients with Chronic Hepatitis C
LB-15
Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration
(SURVEYOR-II, Part 4)
LB-16
Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for
appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an
analysis of multiple real world cohorts totaling >6,500 patients
LB-17
Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for
Hepatitis C: A Review of Spontaneous Post-Marketing Cases
LB-18
Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with
Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or +
daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study)
LB-19
Human FGF19 but not NGM282, an Engineered Variant of FGF19, Causes Hepatocellular Carcinoma (HCC) In A Diet-Induced Mouse Model of Non-Alcoholic
Steatohepatitis (NASH)
LB-20
An RNA-based signature enables high specificity detection of circulating tumor cells in
hepatocellular carcinoma
LB-21
Genome-wide association study identifies a TLL1 variant associated with development
of hepatocellular carcinoma after eradication of hepatitis C virus
LB-23
Reduction in Liver Transplant Wait-Listing in the Era of Direct Acting Anti-Viral Therapy
LB-24
RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of
alpha-1 antitrypsin levels in healthy volunteers
Clinical Hepatocellular Carcinoma (1236-1368)
1244
Changing epidemiology of hepatocellular carcinoma in Singapore – a study of
1,401 cases over 3 decades
1260
Hepatocellular Carcinoma in Patients Cured of Hepatitis C Virus: Less Cirrhosis and
Liver Fat than Expected
1261
Decision Making for Surveillance Interval: Who May Extend Intervals 1 Year After
Curative Treatments for Hepatocellular Carcinoma
1280
Risk factors for liver cancer in chronic hepatitis C are different between the early and
late periods after sustained virological response
1324
Unusually High HCC Rates Among Patients With HCV Cirrhosis After Treatment With
Direct Acting Antivirals
1325
High incidence of hepatocellular carcinoma following successful interferon-free
antiviral therapy for hepatitis C associated cirrhosis
1332
The effect of interferon-free therapy on tumor recurrence in HCV patients with treatment history of hepatocellular carcinoma
1340
The features of hepatocellular carcinoma after IFN free treatment
1360
Risk of Hepatocellular Carcinoma after Antiviral Therapy in Different Sets of Korean
Patients with Chronic Hepatitis C
HCV Therapeutics: Preclinical and Early Development (1448-1456)
1448
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic responce with chronic hepatitis C patients
1451
Clinical Pharmacokinetics of MicroRNA-122 Inhibitor RG-101 Administered as a Single
Dose to Hepatitis C Virus (HCV) and Non-HCV Infected End-Stage Renal Disease
(ESRD) Subjects Undergoing Hemodialysis (HD) Compared to Normal Renal
Function Subjects
1452
AT-337 and AT-511: Novel Potent and Selective Pan-genotypic Purine Nucleotide
Prodrug Inhibitors of the HCV Polymerase
1453
Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent
Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in
Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Result
1454
Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in
Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the
Hepatitis C Virus (HCV) Subgenomic Replicon System
1455
Towards a Single Treatment Cure for HCV: Reformulation of the Pan-genotypic NNI
GSK2878175 as a Long Acting Parenteral (LAP) and In Vivo Proof of Concept
1456
Pharmacokinetics (PK), safety and tolerability of the 2- and 3-direct acting antiviral
(DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered
once-daily (QD) in healthy volunteers (HVs)
HCV: Virology and Pathogenesis (1457-1498)
1457
Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV
Genotype 1 and 4 Infected Patients
1476
The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy
and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with
Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from
ASTRAL-5
1497
Occurrence of polymorphisms and resistant mutations in the NS3, NS5A and NS5B
genes of HCV based on sequences deposited in the European Hepatitis C Virus Database (euHCVdb)
Viral Hepatitis and Orthotopic Liver Transplantation (1630-1637)
1635
100% Virological response with 3D regimen and significant short-term liver stiffness
improvement in patients with recurrent hepatitis C following liver transplantation
Poster presentations
Monday 14 November
08:00 - 17:30: Poster Session IV, Hall C
Presentation time: 12:30 - 14:00
Advanced Practitioners: Practice and Quality Issues (1638-1646)
1640
High HCV Cure Rates After Directly Acting Antivirals In Patients with Chronic Hepatitis
C and Psychiatric Disorders
Health Care Delivery/Access/Quality (1728-1770)
1767
Eliminating Hepatitis C in Spain: Bridging from the National Health Plan
Hepatitis C: New and Approved Agents II (1911-2030)
1911
Patients with HCV GT 1/4 infection and compensated cirrhosis, without baseline NS5A
RASs, could be treated with SOF + NS5A inhibitor for 12 weeks without RBV
1913
The association between race/ethnicity and the effectiveness of direct antiviral agents
for hepatitis C virus infection.
1914
Experience with Direct Antiviral Agents in Hispanic patients with Chronic Hepatitis C
genotype 1 at the Veteran Affairs Caribbean Healthcare System in San Juan
1919
Preliminary Results from TOPAZ-III, A Phase 3b Study Evaluating the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Naïve or Experienced Adults in Brazil with HCV Genotype 1 Infection and Advanced Fibrosis/Cirrhosis
1920
The influence of clinical significant portal hypertension (stage Baveno 2) on safety,
tolerability and efficacy of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin
(PrOD+R) in a real-world large cohort of genotype 1b HCV liver cirrhosis patients
1921
Predictors of Sustained Virological Response (SVR) after Direct Acting Antiviral (DAA)
treatment for Hepatitis C: meta-analysis of 55 studies in 11,419 patients
1926
Efficacy and safety of sofosbuvir and ledipasvir in the treatment of elderly Japanese
patients with hepatitis C genotype 1 infected
1932
Virological response to ombitasvir/paritaprevir/ritonavir+ dasabuvir+ribavirin in 150
patients with mixed cryoglobulinaemia and HCV infection
1934
Genotype 3 Infection In DAA Era: Preliminary Reports Of a Real Life Northern Italy
Network For Viral Hepatitis
1935
Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/
Ritonavir+Dasabuvir±Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients
Treated in Routine Practice
1937
Effect of daclatasvir and asunaprevir combination therapy for chronic hepatitis or
compensated cirrhosis by HCV genotype 1b infection with RAV negative population;
from real world data
1938
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis
or bridging fibrosis treated with different SOF-based DAA regimens: a single centre
experience with a mean follow up of 12 months
1940
High Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection in Elderly
Patients in a National Healthcare System
1941
Efficacy and safety of sofosbuvir-based therapies for cirrhotic and/or elder patients
with hepatitis C virus in Japan
1942
HCV therapy selector webapp: an uniquely simple tool for evidence-based therapy
selection for patients with chronic hepatitis C virus infection
1945
Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several
Real-world Datasets (RWD)
1947
High efficacy of hepatitis C re-treatment strategies after protease inhibitors failure in
real-life settings
1948
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis HCV genotype 1b infection in patients with severe fibrosis; From real world data
1949
Effectiveness of Sofosbuvir/Ledipasvir HCV Treatment Regimens in a Community
Setting
1951
Use of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Advanced Chronic Kidney
Disease (eGFR ≤ 30ml/min): A Case Series
1953
The impact of IL28B polymorphism and HCV NS5A resistance associated variants on
treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings
1955
Protease inhibitor and non-structural protein 5A inhibitor regimen can improve the
health-related quality of life (HRQOL) in Japanese patients with genotype 1b
hepatitis C virus
1959
Glomerular Filtration Rate Change During HCV with Sofosbuvir/Ledipasvir in HCV/
HIV Coinfected Patients Treated with Tenofovir ± Boosted Protease Inhibitor
1963
Efficacy and Safety of oral DAAs HCV therapy in the Elderly
1965
Treatment of Chronic Hepatitis C Genotype 4 -infected Patients with Ombitasvir/
Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
1966
Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in
HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease)
1967
Efficacy and tolerability of IFN-free direct acting antivirals therapy (daclatasvir and
asunaprevir) in chronic hemodialysis patients with chronic hepatitis C
1972
Maximizing access to HCV treatment with direct-acting antiviral agents for uninsured
patients in the United States
1974
Response to Direct Acting Antivirals in African American Liver and Kidney Transplant
Recipients with Genotype 1 Hepatitis C Infection
1975
Ledipasvir-Sofosbuvir for the treatment of Hepatitis C Virus Genotype 1 and 4 Post
Renal Transplantation
1982
Effectiveness of hcv antiviral treatment in patients with cirrhosis or advanced fibrosis
and end-stage kidney disease on dialysis
1985
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: the Canadian National
Experience
1988
OMV/PTV/RTV +/- RBV in Genotype 4, Hard-To-Treat cohorts: real Life Data From
Qatar
1990
Sofosbuvir + simeprevir +/- ribavirin treatment is efficient in genotype 4 chronic
hepatitis C patients: results of a large international cohort
1991
Effectiveness of Sofosbuvir/Ledipasvir and Sofosbuvir/Simeprevir for the Treatment of
Hepatitis C Genotype-1: Real World Analysis
1999
Treatment Patterns Among Hepatitis C Virus Genotype 3 Patients in the United States
2001
Efficacy of direct-acting antiviral agents for treatment of HCV genotype 1 infection in
Hispanics: data from a real-world cohort
2002
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in
real life than expected from clinical trials
2008
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic
hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal
dysfunction; From real world data
2014
Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype 1a and NS5A Y93H
variant in Genotype 3 for interferon-free treatment combinations with direct antiviral
agents (DAAs): Real-life experience from a multicenter study in Sweden and Norway
2017
Effectiveness and security of 3D/2D treatment in HCV/ HIV coinfected cirrhotic
patients
2019
Failure with DDA regimens in a high volume treatment center under real life conditions
2023
Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients
with chronic hepatitis C virus
2024
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA
Regimens: Real-World Experience From the Trio Network
2026
Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience
2028
Clinically Significant Changes in Heart Rate and Adverse Events are Not Observed in
Clinical Trial Patients Receiving SOF-Based Regimens While On Beta-Blockers
SEVIEX160418
AbbVie AB, Box 1523, 171 29 Solna. Tel 08-684 44 600